Core Insights - PacBio has announced the inclusion of its Onso short-read sequencing platform in the 10x Genomics Compatible Partner Program, enhancing the range of sequencing solutions available to researchers globally [1][2][3] Company Overview - PacBio is a leading developer of high-quality genomic sequencing solutions, focusing on accuracy and performance in genomic research [1][4] - The company offers advanced sequencing technologies, including HiFi long-read sequencing and SBB® short-read sequencing, addressing various research applications such as human germline sequencing, oncology, and infectious diseases [4] Partnership Details - The Onso platform is designed for exceptional accuracy in short-read sequencing and is compatible with 10x Genomics' tools for single-cell and spatial biology applications [2][3] - This partnership aims to provide researchers with integrated workflows that enhance insights into genomics and transcriptomics, addressing key challenges in scientific research [2][3] Benefits of Collaboration - Streamlined workflows will allow researchers to access seamless end-to-end solutions by combining PacBio's Onso platform with 10x Genomics' technologies, improving data quality and efficiency [3] - The Onso platform is compatible with 10x Genomics' Single Cell 3' v3.1 assay, enhancing its application in genomic research [3] - PacBio's Onso platform delivers unmatched sequencing accuracy, further enhancing the precision of 10x Genomics' research tools [3][4] Industry Context - 10x Genomics is recognized for its products that accelerate the mastery of biology and advance human health, providing integrated solutions for single-cell and spatial biology [6] - The collaboration between PacBio and 10x Genomics is expected to push the boundaries of genomic science, enabling researchers to explore complex biological systems [3][4]

Company Performance - Pacific Biosciences of California (PACB) closed at $2.06, reflecting a -1.9% change from the previous session, underperforming the S&P 500 which gained 0.47% [1] - Over the past month, PACB shares increased by 12.3%, outperforming the Medical sector which declined by 4.27% and the S&P 500 which rose by 3.48% [2] Upcoming Earnings - The upcoming earnings report for Pacific Biosciences is scheduled for November 7, 2024, with analysts expecting earnings of -$0.20 per share, indicating a year-over-year growth of 25.93% [3] - Revenue is projected to be $41.9 million, down 24.77% from the same quarter last year [3] Full Year Estimates - For the full year, analysts expect earnings of -$0.95 per share and revenue of $168.07 million, representing changes of +14.41% and -16.18% respectively from the previous year [4] Analyst Estimates and Rankings - Recent modifications to analyst estimates for Pacific Biosciences indicate changing business trends, with positive revisions reflecting optimism about the company's profitability [5] - The Zacks Rank system, which evaluates estimate changes, currently ranks Pacific Biosciences at 3 (Hold), with no changes in the consensus EPS estimate over the last 30 days [7] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 94, placing it in the top 38% of over 250 industries [8]

Core Insights - Pacific Biosciences of California, Inc. (PacBio) is experiencing challenges due to stiff competition and macroeconomic concerns, despite a focus on research and development and positive second-quarter 2024 earnings [1][10]. Company Performance - Year-to-date, PacBio's shares have decreased by 79.1%, contrasting with a 6.6% growth in the industry and a 21.9% gain in the S&P 500 [2]. - The company has a market capitalization of $558.7 million and projects a growth rate of 14.4% for 2024, with earnings surpassing the Zacks Consensus Estimate in three of the last four quarters, averaging a surprise of 9.89% [3]. Research and Development Focus - PacBio is committed to enhancing its R&D efforts, aiming to develop new and existing platforms, increase throughput, and reduce costs for customers [4]. - The company is scaling up the manufacturing of its Onso platform to improve commercial execution and meet demand more rapidly [5]. - A new high-throughput short-read platform is in development, expected to serve high-throughput labs and capture a market estimated at over $1 billion annually [6]. - The next-generation SMRT cell is also under development, which will support a new long-read platform with higher throughput than the Revio system [7]. Product Development Activities - PacBio is expanding its presence in the RNA-sequencing market, recently launching the PureTarget repeat expansion panel for examining genes linked to severe neurological conditions [8]. - Collaborations with various organizations, including the National Cancer Centre of Singapore and the University Hospital of Munster, are aimed at enhancing research capabilities and product reach [9]. Financial Results - The second quarter of 2024 showed mixed results, with earnings exceeding estimates but revenues falling short [10]. - There was an increase in service and consumables revenues, but geographical revenue declines in the Americas, Asia-Pacific, and EMEA regions are concerning [11]. Market Conditions - Macroeconomic factors such as rising inflation and global supply-chain constraints are impacting customer sales cycles and may affect revenues throughout 2024 [12]. - The company experiences business seasonality, leading to fluctuations in sales of sequencing instruments [12]. Future Estimates - The Zacks Consensus Estimate for PacBio's adjusted loss per share for the third quarter of 2024 remains unchanged at 20 cents, with revenue estimates at $41.9 million, reflecting a 24.8% decrease from the previous year [13].

Pacific Biosciences, Inc. (PACB) , popularly known as PacBio, has signed a new Research Collaboration Agreement with the National Cancer Centre of Singapore (NCCS) to enhance Asian cancer research. Leveraging PacBio's Onso short-read sequencing platform, the collaboration aims to enable researchers to profile the genomic landscape of prevalent cancers, including gastrointestinal stromal tumors. PacBio's partner, Diethelm Keller Siber Hegner (DKSH), a Swiss company specializing in market expansion services, ...

Core Viewpoint - PacBio will hold its quarterly conference call to discuss its third quarter 2024 financial results on November 7, 2024, at 4:30 pm Eastern Time [1] Company Overview - Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a leading life science technology company that designs, develops, and manufactures advanced sequencing solutions [2] - The company focuses on two core technologies: HiFi long-read sequencing and SBB® short-read sequencing, emphasizing accuracy, quality, and completeness [2] - PacBio's products are utilized in various research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications [2]

Company Overview - Pacific Biosciences of California (PACB) closed at $1.81, reflecting a +0.56% change from the previous trading day's close, outperforming the S&P 500's gain of 0.54% [1] - Over the past month, PACB shares have increased by 6.51%, surpassing the Medical sector's gain of 4.37% and the S&P 500's gain of 4.86% [2] Financial Performance Expectations - The upcoming financial results are anticipated to show an EPS of -$0.20, which represents a 25.93% increase compared to the same quarter last year. Revenue is expected to be $41.9 million, indicating a 24.77% decrease year-over-year [3] - For the entire year, the Zacks Consensus Estimates forecast an EPS of -$0.95 and revenue of $168.07 million, reflecting changes of +14.41% and -16.18% respectively compared to the previous year [4] Analyst Estimates and Market Sentiment - Recent changes to analyst estimates for PACB suggest a shifting business landscape, with positive revisions indicating optimism about the company's outlook [5] - The Zacks Rank system, which correlates estimate revisions with share price momentum, currently ranks PACB as 3 (Hold), with a 9.17% decrease in the consensus EPS estimate over the last 30 days [6][7] Industry Context - The Medical - Instruments industry, which includes PACB, holds a Zacks Industry Rank of 63, placing it in the top 25% of over 250 industries. This ranking indicates that top-rated industries tend to outperform lower-rated ones by a factor of 2 to 1 [8]

Pacific Biosciences of California, Inc. (PACB) or PacBio recently announced a collaboration with HiFi Solves Sub-Fertility Consortium, led by KK Women's and Children's Hospital in Singapore. The consortium will use PACB's HiFi long-read sequencing to pioneer advancements in diagnosing and treating subfertility and recurrent pregnancy loss (RPL). The consortium includes experts from five leading centers across the AsiaPacific region and leverages DNAstack's federated data platform to ensure secure, global co ...

Pacific Biosciences of California, Inc. (PACB) has announced a collaboration with the University Hospital of Munster to use its Revio HiFi sequencing system in advancing research on male infertility and rare diseases. Munster is pioneering long-read whole genome sequencing in Germany, integrating it into research and diagnostics. This initiative will explore complex genetic issues, including the Y chromosome's role in male infertility, and support Germany's GenomeDE Modellvorhaben project. The results will ...

SINGAPORE, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The HiFi Solves Sub-fertility Consortium, an innovative collaboration involving five leading centers across the Asia-Pacific region, announces work aimed at redefining the landscape of fertility research. Utilizing PacBio HiFi long-read sequencing, the consortium, led by KK Women's and Children's Hospital (KKH) in Singapore, is pioneering the use of PacBio HiFi long-read sequencing to enhance the diagnosis and treatment of subfertility and recurrent miscarriages ...

Core Insights - PacBio announced a collaboration with the University Hospital of Münster to advance male infertility and rare disease research using long-read whole genome sequencing with the Revio HiFi sequencing system [1][2][4] - The University of Münster aims to sequence 500 male infertility patients over the next year and will also conduct trio sequencing for rare disease families [3][4] Company Developments - The University of Münster's Center of Medical Genetics will utilize the Revio system, marking it as the first in Germany to implement long-read whole genome sequencing in a translational research and diagnostic context [2][3] - PacBio's Revio system is expected to provide critical insights into the Y chromosome's role in male infertility, addressing complex genetic issues that have been challenging to study [3][4] Industry Impact - The collaboration supports Germany's GenomeDE Modellvorhaben project, which aims to integrate genomic medicine into standard patient care, and extends research efforts internationally through the International Male Infertility Genomics Consortium [2][3] - The advancements in male infertility and rare disease research are particularly relevant for aging European populations, where declining birth rates are putting pressure on healthcare systems [3]